Kiwi, Its a Catch-22. The group that did the best on Vascepa was
white males on med-high statins under age 60. Seems the sooner one
is taking Vascepa, the greater the benefit. The fact that the seperation
curves don't seem to flatten out is another indication of this. Too bad
that many patients being given a script for Vascepa stop taking it for
one reason or another, usually because of the out of pocket cost.
The people who benefit the most are those with the lowest blood EPA
levels...every person at risk for CVD should be on Vascepa regrdless
of Trig levels. The key for AMRN (or its BP acquirer) is to convince
patients it is to their benefit to stay on Vascepa (nor give it up) and
to attempt to find a tolerable statin med and stay on that as well.
Sadly, some older patients may be too damaged to do enough good for
them because they will not have enough time being on the drug to reverse
some of the damage that would prevent an event. The wider the label
is the more people who will ultimately benefit. Restricting the label
in any way may needlessly cost lives and events. Better to have too
many people taking Vascepa who might not need it than too few who really
would benefit.
Market Data 
Markets 
AI
